Search results
Results from the WOW.Com Content Network
In 1997, Gideon Richter withdrew from efforts to manufacture mifepristone in the United States following opposition from pro-life groups, which led to Danco filing a breach of contract lawsuit. [ 6 ] On September 28, 2000, Danco Laboratories received approval to distribute mifepristone (under the Mifeprex brand name) from the US Food and Drug ...
[62] Following use by 34,000 women in France from April 1988 to February 1990 of mifepristone distributed free of charge, Roussel-Uclaf began selling Mifegyne (mifepristone) to hospitals in France in February 1990 at a price (negotiated with the French government) of US$48 (equivalent to $111.94 in 2023) per 600-mg dose.
In 2000, GenBioPro's generic version of mifepristone was approved for medication abortion, as part of a two-drug regimen in combination with misoprostol. In 2023, GenBioPro sued the FDA to obtain a legal judgement confirming that mifepristone could continue to be sold, in spite of anti-abortion laws passed in some states. [1]
The median price increase of the drugs being hiked Jan. 1 is 4.5%, which is in line with the median for all price increases last year. Drugmakers to raise US prices on over 250 medicines starting ...
Some drugs target the hormones involved in hunger, appetite control and metabolism — like leptin, ghrelin, insulin and glucagon-like peptide-1 (GLP-1). This can help you reduce your overall food ...
Antiglucocorticoid drugs are a class of medications that act to reduce the effects of glucocorticoids, primarily cortisol, in the body. [1] They include direct glucocorticoid receptor antagonists such as mifepristone and synthesis inhibitors such as metyrapone , ketoconazole , and aminoglutethimide .
The case challenges the FDA’s regulation of mifepristone, a prescription-only drug approved in 2000 with a stellar safety record that is used in 63% of all U.S. abortions.
A 2013 systematic review which included 45,000 women who used the 200 mg mifepristone followed by misoprostol combination found that less than 0.4% had serious complications requiring hospitalization (0.3%) and/or blood transfusion (0.1%).